참고문헌
- Balta AZ, Filiz AI, Kurt Y, et al (2012). Prognostic value of oncoprotein expressions in thyroid papillary carcinoma. Med Oncol, 29, 734-41. https://doi.org/10.1007/s12032-011-9969-x
- Cvejic D, Selemetjev S, Savin S, et al (2008). Apoptosis and proliferation related molecules (Bcl-2, Bax, p53, PCNA) in papillary microcarcinoma versus papillary carcinoma of the thyroid. Pathology, 40, 475-80. https://doi.org/10.1080/00313020802026989
- Dellis RA, Lloyd RV, Heitz U, Eng C (2004). Pathology and Genetics. Tumours of Endocrine organs. Lyon: World Health Organization, IARC Press.
- El Demellawy D, Nasr A, Alowami S (2008). Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. Diagn Pathol, 6, 3-5.
- Gauchotte G, Philippe C, Lacomme S, et al (2011). BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis. Pathology, 43, 447-52. https://doi.org/10.1097/PAT.0b013e3283486178
- Hamzany Y, Soudry E, Strenov Y, et al (2012). Early death from papillary thyroid carcinoma. Am J Otolaryngol, 33, 104-8. https://doi.org/10.1016/j.amjoto.2011.04.002
- Hansen JE, Fischer LK, Chan G, et al (2008). Antibody-mediated p53 protein therapy prevents liver metastasis in vivo. Cancer Res, 67, 1769-74.
- Horie S, Maeta H, Endo K, et al (2001). Overexpression of p53 protein and MDM2 in papillary carcinomas of the thyroid: Correlations with clinicopathologic features. Pathol Int, 51, 11-5. https://doi.org/10.1046/j.1440-1827.2001.01159.x
- Hosal SA, Apel RL, Freeman JL, et al (1997). Immunohistochemical localization of p53 in human thyroid neoplasms: correlation with biological behavior. Endocr Pathol, 18, 21-8.
- Jung TS, Kim K-S, Oh YL, Jung JH (2007). p53, p21 and Bcl-2 protein expression and the clinical significance in papillary thyroid carcinoma. J Korean Endo Soc, 22, 98-104. https://doi.org/10.3803/jkes.2007.22.2.98
- Karlidag T, Cobanoglu B, Keles E, et al (2007). Expression of Bax, p53, and p27/kip in patients with papillary thyroid carcinoma with or without cervical nodal metastasis. Am J Otolaryngol, 28, 31-6. https://doi.org/10.1016/j.amjoto.2006.06.008
- Liu MC and Gelmann EP (2002). P53 gene mutations: case study of a clinical marker for solid tumors. Semin Oncol, 29, 246-57. https://doi.org/10.1053/sonc.2002.32900
- Kim BS, Kang KH, Lim YA, Kim LS (2009). Clinical significance of p53, Ki-67 and Galectin-3 expressions in papillary thyroid carcinoma. J Korean Surg Soc, 77, 29-36. https://doi.org/10.4174/jkss.2009.77.1.29
- Morita N, Ikeda Y, Takami H (2008). Clinical significance of p53 protein expression in papillary thyroid carcinoma. World J Surg, 32, 2617-22. https://doi.org/10.1007/s00268-008-9756-9
- Nasir A, Catalano E, Calafati S, et al (2004). Role of p53, CD44V6 and CD57 in differentiating between benign and malignant follicular neoplasms of the thyroid. in vivo, 18, 189-95.
- Omar E, Madhavan M, Othman NH (2004). Immunohistochemical localisation of RET and p53 mutant protein of thyroid lesions in a North-Eastern Malaysian population and its prognostic implications. Pathology, 36, 152-9. https://doi.org/10.1080/00313020410001671993
- Parameswaran R, Brooks S, Sadler GP (2010). Molecular pathogenesis of follicular cell derived thyroid cancers. Int J Surg, 8, 186-93. https://doi.org/10.1016/j.ijsu.2010.01.005
- Park KY, Koh JM, Kim YI, et al (1998). Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population. Clin Endocrinol (Oxf), 49, 317-23. https://doi.org/10.1046/j.1365-2265.1998.00515.x
- Park YK, Park HR, Chi SG, Ushigome S, Unni KK (2001). Overexpression of p53 and absent genetic mutation in clear cell chondrosarcoma. Int J Oncol, 19, 353-7.
- Park MI, Kang DY (2006). Usefulness of Galectin-3, cytokeratin 19, p53 and Ki-67 for the differential diagnosis of thyroid tumors. Korean J Pathol, 40, 86-92.
- Tan A, Etit D, Bayol U, Altinel D, Tan S (2011). Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma. Ann Diagn Pathol, 15, 108-16. https://doi.org/10.1016/j.anndiagpath.2010.11.005
- Zafon C, Obiols G, Castellvi J, et al (2007). Clinical significance of RET/PTC and p53 protein expression in sporadic papillary thyroid carcinoma. Histopathology, 50, 225-31. https://doi.org/10.1111/j.1365-2559.2006.02555.x
피인용 문헌
- No Evidence of Association of the Arg72Pro p53 Gene Polymorphism with Cancer Risk in the Saudi Population: a Meta-Analysis vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5663
- The TP53 intron 6 G13964C Polymorphism and Risk of Thyroid and Breast Cancer Development in the Iranian Azeri Population vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.3073
- p53, Cyclin D1, p21 (WAF1) and Ki-67 (MIB1) Expression at Invasive Tumour Fronts of Oral Squamous Cell Carcinomas and Development of Local Recurrence vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.1243
- Decreased expression of p27 is associated with malignant transformation and extrathyroidal extension in papillary thyroid carcinoma vol.37, pp.3, 2016, https://doi.org/10.1007/s13277-015-4163-y
- Correlation of BRAF mutation and SUVmax levels in thyroid cancer patients incidentally detected in 18F-fluorodeoxyglucose positron emission tomography vol.55, pp.1, 2017, https://doi.org/10.1007/s12020-016-1128-x